Abstract
The Blood-Brain Barrier (BBB) limits transportation to the brain of possible treatment moieties. Specific stimulation of the brain through olfactory and trigeminal neural pathways by BBB has been taken into consideration for the development of a wide spectrum of brain therapeutics. The intranasal delivery path delivers the drugs through the brain, eliminating any side effects and increasing neurotherapeutics performance. Diverse drug delivery systems (DDDss) for reaching the brain via the nasal route have been researched over the past few decades. Large-scale molecular biologics, such as Deoxyribonucleic acid (DNA), gene vectors, and stem cells, can be administered intranasally, as a method for the management of a range of CNS illnesses, including stroke, Parkinson's diseases, multiple sclerosis, Migraine, Alzheimer's diseases, epilepsy, and mental disorders. New DDSs, including nanoparticles, liposomes, and polymeric micelles, have acquired potentials in the nasal mucosa and central nervous system (CNS), as effective means of concentrating the brain without toxicity. Differential nasal cavity structures posed a significant obstacle in ineffective drugs beyond the nasal valve. Pharmaceutical firms have increasingly used emerging techniques for the production of new nasal pharmaceutical drugs to overcome these obstacles. This review aims to identify the new advances in the nasal administration of brain-based DDSs for Migraines.
Highlights
Central nervous system (CNS) dysfunction means the victims, their families, and the community as a tremendous mental, financial and social pressure
The numerous "diseases of the mind" have significant deep-rooted issues for improved therapeutic strategies, and central nervous system (CNS) therapy can be effective for other disorders [1]
This study demonstrates that dextran was directly taken to the brain and stopped blood and Blood-Brain Barrier (BBB) from going through it, but it does not reveal the direction of entry into the brain of the molecule
Summary
Central nervous system (CNS) dysfunction means the victims, their families, and the community as a tremendous mental, financial and social pressure. The complex pathophysiology of neurological disorders, trouble reaching the brain with large as well as small molecular drugs, and risk, uncertainty, and massive costs of controlled clinical trials present major obstacles in the research and production of novel drugs for brain disorders [2]. These issues have caused a drop in the pharmaceutical sector in recent years, with decreased funding in pharmaceutical production for many CNS conditions being identified. Oral preparations have a short half-of 1–2 h, with the drug-exposed to hepatic first-pass metabolism and renal functions cleared away [5]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
